1stOncology™: Cancer Intelligence Service – Page 13822 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Iovance Biotherapeutics to Participate in Upcoming Conferences in May

On May 2, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that the company plans to participate in the following conferences in May (Press release, Iovance Biotherapeutics, MAY 2, 2019, View Source;p=irol-newsArticle&ID=2396790 [SID1234535570]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

NYAS Frontiers in Cancer Immunotherapy in New York, May 14-15, 2019
Panel Presentation: Will CAR-T Cell Therapies, Bispecific Antibodies, or TILs Be More Beneficial for Solid Tumors?
Session: Session 4, Breakout Track B
Location: The New York Academy of Sciences
Date/time: Wednesday, May 15, at 1:00 p.m. EDT

Oppenheimer Oncology Insight Summit in New York, May 16, 2019
Location: InterContinental New York Barclay Hotel

AACR Bladder Cancer: Transforming the Field Conference in Denver, May 18-21, 2019
Poster Presentation: Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from advanced bladder cancer for adoptive immunotherapy
Authors: Qiang John Li et al.
Session Type: Poster Session A
Abstract Number: A05
Location: Grand Hyatt Denver
Date/Time: Sunday, May 19, from 12:30 p.m. – 3:00 p.m. MDT

20th Annual B. Riley FBR Investor Conference in Beverly Hills, CA, May 22-23, 2019
Location: The Beverly Hilton Hotel
Date/Time: Thursday, May 23, at 9:00 a.m. PDT
A live and archived webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics’ website at View Source

Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019

On May 2, 2019 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that it will report first quarter 2019 financial results on Thursday, May 9, 2019 (Press release, Karyopharm, MAY 2, 2019, View Source [SID1234535569]). Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 9, 2019 to discuss the financial results and other company updates.

To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least 10 minutes prior to the start time and refer to conference ID 9756776. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company’s website, View Source An archived webcast will be available on the Company’s website approximately two hours after the event.

Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call

On May 2, 2019 Spectrum Pharmaceuticals (NasdaqGS: SPPI), reported it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company’s business, and discuss expectations for the future on Thursday, May 9, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific (Press release, Spectrum Pharmaceuticals, MAY 2, 2019, View Source [SID1234535568]).

Conference Call

Thursday, May 9, 2019 @ 4:30 p.m. Eastern/1:30 p.m. Pacific

Domestic:
(877) 837-3910, Conference ID# 4290388

International:

(973) 796-5077, Conference ID# 4290388

For interested individuals unable to join the call, a replay will be available from May 9, 2019 @ 7:30 p.m. ET/4:30 p.m. PT through May 16, 2019 until 11:59 p.m. ET/8:59 p.m. PT.

Domestic Replay Dial-In #:

(855) 859-2056, Conference ID# 4290388
International Replay Dial-In #:

(404) 537-3406, Conference ID# 4290388
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals’ website: View Source on May 9, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

NantHealth to Report 2019 First-Quarter Financial Results and Host Conference Call on Thursday, May 9

On May 2, 2019 NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, reported that it will report financial results for its 2019 first quarter on Thursday, May 9, 2019, after market close (Press release, NantHealth, MAY 2, 2019, View Source;p=irol-newsArticle&ID=2396774 [SID1234535567]). NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company’s performance.

The conference call will be available to interested parties by dialing 844-309-3709 from the U.S. or Canada, or 281-962-4864 from international locations, passcode 6159197. The call will be broadcast via the Internet at www.nanthealth.com.

Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019

On May 2, 2019 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, reported that it will report financial results and provide an update on recent progress on its development programs on Thursday, May 9th, 2019 at 8:00 a.m. ET before the market opens (Press release, Reata Pharmaceuticals, MAY 2, 2019, View Source [SID1234535566]).

The conference call will be accessible by dialing (844)348-3946 (toll-free domestic) or (213)358-0892 (international) using the access code: 5177169. The webcast link is View Source

First quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at View Source and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event through the Investors section of the company’s website at View Source